CSL Ltd
Brian McNamee, mere mortal
Because the CSL chair is so revered, nobody will say the quiet part out loud.
|
CSL Ltd
4 articles
CSL Ltd
The unravelling of CSL
The company is undisputed king of the blood products jungle no longer.
|
Summer Series
Investing in 2025: beyond the laws of reality
Why this year the market felt untethered from probability or profit.
|
CSL Ltd
CSL’s post-Perreault paroxysm
Our greatest biotech export is at the crossroads, or was it just t-boned?
|